

Form PTO-1449 (modified)		Atty. Docket No.: EPCL:015US	Serial No.: 10/599,937
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Anna CEDERHOLM Johan FROSTEGÅRD	
		Filing Date: October 13, 2006	Group: 1656
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1-2</i>		Other Art <i>See Page 2-5</i>

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A1	2003/0109420	6/12/03	Valkirs <i>et al.</i>	514	2	5/4/02
	A2	2003/152513	8/14/03	Blankenberg <i>et al.</i>	424	1.49	9/6/02
	A3	2003/170241	9/11/03	Aukrust <i>et al.</i>	424	145.1	2/20/03
	A4	2004/0042959	3/4/04	Montaldo <i>et al.</i>	424	1.11	8/28/02
	A5	2004/0203083	10/14/04	Buechler & Maisel	435	7.92	12/3/03
	A6	2005/0013778	1/20/05	Green & Steinmetz	424	9.6	4/6/04
	A7	5,632,986	5/27/97	Tait & Fujikawa	424	94.64	5/15/95
	A8	5,767,247	6/16/98	Kaneko <i>et al.</i>	530	388.2	10/22/96
	A9	5,968,477	10/19/99	Kasina <i>et al.</i>	424	1.69	7/26/96
	A10	6,232,440	5/15/01	Hillman <i>et al.</i>	530	350	4/20/99
	A11	6,284,475	9/4/01	Rand	435	7.21	7/10/98
	A12	6,613,328	9/2/03	Co & Vasquez	424	145.1	1/24/01

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Language
	B1	EP 0965840	12/22/99	EP	English
	B2	EP 1153611	11/14/01	EP	English
	B3	EP 1379266	4/18/07	EP	English
	B4	WO 95/34315	12/21/95	WIPO	English
	B5	WO 98/29442	7/9/98	WIPO	English
	B6	WO 99/19470	4/22/99	WIPO	English
	B7	WO 02/067857	9/6/02	WIPO	English
	B8	WO 03/103577	12/18/03	WIPO	English

25792870.1

EXAMINER:	/Sharon Wen/	DATE CONSIDERED:	10/25/2009
------------------	--------------	-------------------------	------------

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.W./

Form PTO-1449 (modified)		Atty. Docket No.: EPCL:015US	Serial No.: 10/599,937
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Anna CEDERHOLM Johan FROSTEGÅRD	
		Filing Date: October 13, 2006	Group: 1656
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1-2</i>		Other Art <i>See Page 2-5</i>

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Language
	B9	WO 04/001384	3/4/04	WIPO	Japanese (English Abstract)
	B10	WO 04/006963	1/22/04	WIPO	English
	B11	WO 04/018670	12/31/03	WIPO	English

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	Alves and Ames, "Atherosclerosis, oxidative stress and auto-antibodies in systemic lupus erythematosus and primary antiphospholipid syndrome," <i>Immunobiology</i> , 207:23-28, 2003.
	C2	Asherson <i>et al.</i> , "The 'primary' antiphospholipid syndrome: major clinical and serological features," <i>Medicine</i> , 68:366-374, 1989.
	C3	Binder, "Defining innate and adaptive immune mechanisms in the atheroprotective effect of immunization with oxidized low-density lipoproteins," <i>Dissertation Abstracts International</i> , 63(9):4109, 2002.
	C4	Binder, "Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between <i>streptococcus pneumoniae</i> and oxidized LDL," <i>Nature Medicine</i> , 9(6):736-743, 2003.
	C5	Brownawell, "Identification of annexin-binding proteins," <i>Dissertation Abstracts International</i> , 59(2):491, 1998.
	C6	Cederholm <i>et al.</i> , "Decreased binding of annexin V to endothelial cells: A potential mechanism in atherothrombosis of patients with systemic lupus erythematosus," <i>Arterioscler. Thromb. Vasc. Biol.</i> , 25:198-203, 2005.
	C7	Cushman, "Hormone therapies and vascular outcomes: who is at risk?" <i>Journal of Thrombosis and Thrombolysis</i> , 16(1/2): 87-90, 2003.
	C8	Frostegård <i>et al.</i> , "Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines," <i>Atherosclerosis</i> , 145:33-43, 1999.

25792870.1

EXAMINER:	/Sharon Wen/	DATE CONSIDERED:	10/25/2009
------------------	--------------	-------------------------	------------

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.W./

Form PTO-1449 (modified)		Atty. Docket No.: EPCL:015US	Serial No.: 10/599,937
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Anna CEDERHOLM Johan FROSTEGÅRD	
		Filing Date: October 13, 2006	Group: 1656
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1-2</i>	Other Art <i>See Page 2-5</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C9	Goldenberg, <i>et al.</i> , "Human antibody to phosphorylcholine is bactericidal against Haemophilus influenzae," <i>Abstracts of the General Meeting of the American Society for Microbiology</i> , 103:D-116, 2003.
	C10	Halpern <i>et al.</i> , "Human anti-phosphorylcholine antibodies share idiotypes and are self-binding," <i>J. Clin. Invest.</i> , 88(2):476-482, 1991.
	C11	Hughes, "Thrombosis, abortion, cerebral disease, and the lupus anticoagulant," <i>British Medical Journal</i> , 287:1088-1089, 1983.
	C12	Kim <i>et al.</i> , "I-PLA2 activation during apoptosis promotes the exposure of membrane lysophosphatidylcholine leading to binding by natural immunoglobulin M antibodies and complement activation," <i>J. Exp. Med.</i> , 196(5):655-665, 2002.
	C13	Li <i>et al.</i> , "Differential effects of apolipoprotein A-I-mimetic peptide on evolving and established atherosclerosis in apolipoprotein e-null mice," <i>Circulation</i> , 110(12):1701-1705, 2004.
	C14	Manzi <i>et al.</i> , "Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus," <i>Arthritis & Rheumatism</i> , 42(1):51-60, 1999.
	C15	Mari <i>et al.</i> , "Annexin V, a new therapeutic tool in atherosclerosis," <i>49th Annual Meeting of the Society of Nuclear Medicine</i> , 2002.
	C16	Meers, "Annexin binding to lipid assemblies," <i>In: Annexins: Molecular Structure to Cellular Function</i> , 339:97-119, 1996.
	C17	Merched <i>et al.</i> , "Macrophage-specific p53 expression plays a crucial role in atherosclerosis development and plaque remodeling," <i>Atheroscler. Thromb. Vasc. Biol.</i> , 23:1608-1614, 2003.
	C18	Neto, <i>et al.</i> , "Passive immunization with monoclonal antibody (IgM) to phosphorylcholine, an oxidized LDL related neoantigen, reduces accelerated atherosclerosis in a vein-graft model in ApoE null mice," <i>American Heart Association</i> , 2004.
	C19	Nicoletti <i>et al.</i> , "Immunoglobulin treatment reduces atherosclerosis in apo E knockout mice," <i>J. Clin. Invest.</i> , 102(5):910-918, 1998.
	C20	Nojima <i>et al.</i> , "Association between the prevalence of antibodies to β_2 -glycoprotein I, prothrombin, protein C, protein S, and annexin V in patients with systemic lupus erythematosus and thrombotic and thrombocytopenic complications," <i>Clinical Chemistry</i> , 47(6):1008-1015, 2001.

25792870.1

EXAMINER: /Sharon Wen/	DATE CONSIDERED: 10/25/2009
-------------------------------	------------------------------------

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.W./

Form PTO-1449 (modified)		Atty. Docket No.: EPCL:015US	Serial No.: 10/599,937
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Anna CEDERHOLM Johan FROSTEGÅRD	
		Filing Date: October 13, 2006	Group: 1656
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1-2</i>	Other Art <i>See Page 2-5</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C21	Petri <i>et al.</i> , "Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus," <i>The Lancet</i> , 348:1120-1124, 1996.
	C22	Rand <i>et al.</i> , "Antiphospholipid antibodies accelerate plasma coagulation by inhibiting annexin-V binding to phospholipids: A 'lupus procoagulant' phenomenon," <i>Blood</i> , 92(5):1652-1660, 1998.
	C23	Rand <i>et al.</i> , "Antiphospholipid immunoglobulin G antibodies reduce annexin-V levels on syncytiotrophoblast apical membranes and in culture media of placental villi," <i>Am. J. Obstet. Gynecol.</i> , 177:918-923, 1997.
	C24	Rand <i>et al.</i> , "Human monoclonal antiphospholipid antibodies disrupt the annexin A5 anticoagulant crystal shield on phospholipid bilayers," <i>American Journal of Pathology</i> , 163(3): 1193-1200, 2003.
	C25	Rand, "Antiphospholipid antibody-mediated disruption of the annexin-V antithrombotic shield: a thrombogenic mechanism for the antiphospholipid syndrome," <i>J. Autoimmune</i> , 15:107-111, 2000.
	C26	Rand, "The pathogenic role of annexin-V in the antiphospholipid syndrome," <i>Current Rheumatology Reports</i> , 2(3):246-251, 2000.
	C27	Rimon <i>et al.</i> , "Increased surface phosphatidylserine is an early marker of neuronal apoptosis," <i>Journal of Neuroscience Research</i> , 48(6):563-570, 1997.
	C28	Romisch <i>et al.</i> , "In-vivo antithrombotic potency of placenta protein 4 (annexin V)," <i>Thrombosis Research</i> , 61:93-104, 1991.
	C29	Rose and Afanasyeva, "Autoimmunity: busting the atherosclerotic plaque," <i>Nature Medicine</i> , 9(6):641-642, 2003.
	C30	Ross, "Atherosclerosis – an inflammatory disease," <i>N. Engl. J. Med.</i> , 340:115-126, 1999.
	C31	Rossouw, "Coronary heart disease in menopausal women: implications of primary and secondary prevention trials of hormones," <i>Maturitas</i> , 51(1):51-63, 2005.
	C32	Sheldon and Chen, "Annexin/protein interactions: clues for function," <i>In: Annexins: Molecular Structure to Cellular Function</i> , 341:133-141, 1996.
	C33	Sherer and Shoenfeld, "Immunomodulation for treatment and prevention of atherosclerosis," <i>Autoimmunity Reviews</i> , 1(1-2):21-27, 2002.

25792870.1

EXAMINER:	/Sharon Wen/	DATE CONSIDERED:	10/25/2009
-----------	--------------	------------------	------------

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.W./

Form PTO-1449 (modified)		Atty. Docket No.: EPCL:015US	Serial No.: 10/599,937
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Anna CEDERHOLM Johan FROSTEGÅRD	
		Filing Date: October 13, 2006	Group: 1656
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1-2</i>	Other Art <i>See Page 2-5</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C34	Stach <i>et al.</i> , "Treatment with annexin V increases immunogenicity of apoptotic human T-cells in Balb/c mice," <i>Cell Death and Differentiation</i> , 7:911-915, 2000.
	C35	Stratton <i>et al.</i> , "Selective uptake of radiolabeled annexin V on acute porcine left atrial thrombi," <i>Circulation</i> , 92:3113-3121, 1995.
	C36	Svenungsson <i>et al.</i> , "Elevated triglycerides and low levels of high-density lipoprotein as markers of disease activity in association with up-regulation of the tumor necrosis factor α /tumor necrosis factor receptor system in systemic lupus erythematosus," <i>Arthritis & Rheumatism</i> , 48(9):2533-2540, 2003.
	C37	Svenungsson <i>et al.</i> , "Risk factors for cardiovascular disease in systemic lupus erythematosus," <i>Circulation</i> , 104:1887-1893, 2001.
	C38	Svenungsson <i>et al.</i> , "TNF- α : a link between hypertriglyceridaemia and inflammation in SLE patients with cardiovascular disease," <i>Lupus</i> , 12:454-461, 2003.
	C39	Thiagarajan <i>et al.</i> , "Inhibition of arterial thrombosis by recombinant annexin V in a rabbit carotid artery injury model," <i>Circulation</i> , 96(7):2339-2347, 1997.
	C40	Vaarala <i>et al.</i> , "Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men," <i>Circulation</i> , 91:23-27, 1995.
	C41	Wagner <i>et al.</i> , "The applicability of hormonal effects on atherosclerosis in animals to heart disease in postmenopausal women," <i>Seminars in Reproductive Medicine</i> , 23(2):149-156, 2005.
	C42	Wu <i>et al.</i> , "Antibodies to platelet-activating factor are associated with borderline hypertension, early atherosclerosis and the metabolic syndrome," <i>Journal of Internal Medicine</i> , 246:389-397, 1999.
	C43	Wu <i>et al.</i> , "Anti-idiotypes to oxidized LDL antibodies in intravenous immunoglobulin preparations – possible immunomodulation of atherosclerosis," <i>Autoimmunity</i> , 36(2):91-97, 2003.

25792870.1

EXAMINER:	/Sharon Wen/	DATE CONSIDERED:	10/25/2009
-----------	--------------	------------------	------------

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.W./